Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Inventory Average (2021 - 2025)

Historic Inventory Average for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $121.9 million.

  • Apellis Pharmaceuticals' Inventory Average fell 1095.97% to $121.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.9 million, marking a year-over-year decrease of 1095.97%. This contributed to the annual value of $113.9 million for FY2024, which is 185.72% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Inventory Average stood at $121.9 million for Q3 2025, which was down 1095.97% from $101.7 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Inventory Average high stood at $157.0 million for Q2 2024, and its period low was $2.7 million during Q3 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Inventory Average value was $94.4 million (recorded in 2023), while the average stood at $86.0 million.
  • Its Inventory Average has fluctuated over the past 5 years, first soared by 190081.36% in 2022, then plummeted by 4673.34% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Inventory Average stood at $9.0 million in 2021, then surged by 709.81% to $72.7 million in 2022, then surged by 68.36% to $122.5 million in 2023, then decreased by 17.33% to $101.2 million in 2024, then grew by 20.43% to $121.9 million in 2025.
  • Its Inventory Average was $121.9 million in Q3 2025, compared to $101.7 million in Q2 2025 and $81.9 million in Q1 2025.